11 - 17 February 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Disease modifying drugs and clinically isolated syndrome
Fampridine response changes over time
Disability assistance at airports lacking
Disease modifying drugs compared
An international study compared Lemtrada (alemtuzumab) with Tysabri (natalizumab), Gilenya (fingolimod) and Rebif. The relapse rate on Lemtrada was lower than that for Gilenya and Rebif, though similar to that for Tysabri. The risk of disability accumulation was similar across all four drugs. The chance for periods of improvement in disability was higher with Tysabri, with the other three drugs roughly the same
Source: MedWire News
MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS